May 28, 2014
/PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY), a vertically-integrated specialty pharmaceutical company dedicated to delivering high quality, novel, and customizable medicines to physicians and patients at accessible prices, announced today its attendance at the upcoming 2014 Kiawah Eye Meeting (
Kiawah Island, SC
May 29-31, 2014
The 2014 Kiawah Eye Meeting, a CME symposium, offers ophthalmologists the opportunity to
learn about the latest breakthroughs and advancements in all subspecialties of ophthalmology, presented by leading physicians and researchers in the field. While there, Imprimis will continue its Go Dropless™ campaign ( http://dropless.com/), which has been created to inform ophthalmologists about dropless ophthalmic surgery opportunities and the unique injectable compounded drug formulations the company has developed in conjunction with physicians and pharmacists. Information about Imprimis and its proprietary formulations will be available to conference attendees who visit the Imprimis exhibit (Booth #C21).
Imprimis' proprietary patent-pending ophthalmic formulations and non-proprietary formulations are currently being compounded at its pharmacy and shipped to
25 states and territories
with a physician's prescription
, and the pharmacy has applications to operate as an out-of-state pharmacy submitted and pending in 15 additional states.
The Kiawah Eye Meeting attendance continues the strong momentum Imprimis has been building with the ophthalmic clinical community from previous meetings. Through attending these key clinical symposia the company has added to the active customer base and generated new interest from hundreds of ophthalmologists in a variety of subspecialties.
For those interested in learning more about the ophthalmic formulations or scheduling meetings with Imprimis at the Kiawah Eye Meeting, please register at
ABOUT DROPLESS OPHTHALMIC SURGERY FORMULATIONS
Imprimis' proprietary ophthalmic formulations use patent-pending technologies to uniquely allow for the combination of drugs such as triamcinolone and moxifloxacin that do not typically distribute evenly in a suspension. Two compounded antibiotic and steroid formulations currently available
in single, injectable, intraocular doses administered during ocular surgery include preservative-free combinations of triamcinolone acetonide and moxifloxacin hydrochloride and triamcinolone acetonide, moxifloxacin hydrochloride and vancomycin.
The relative strengths of the active ingredients can be tailored to individual patients. Intraoperative administration of drugs has been shown to reduce both non-compliance and patient error, significantly lessening the surgeon's concern and elevating the patient's experience with cataract surgery.
Physicians have prescribed Imprimis' proprietary formulations for use in thousands of cataract surgeries, and have reported advantages including reduction of compliance concerns and reduction of staff and chair time spent on instructions and follow-up with post-operative surgical patients and pharmacists.
ABOUT IMPRIMIS PHARMACEUTICALS
San Diego-based Imprimis Pharmaceuticals, Inc. (Nasdaq: IMMY) is a vertically integrated specialty pharmaceutical company dedicated to delivering high quality, novel, and customizable medicines to physicians and patients at accessible prices. Imprimis is pioneering a new commercial pathway using compounding pharmacies for the formulation and distribution of its proprietary drug therapies, which include formulations in ophthalmology, wound management and urology. For more information, please visit www.imprimispharma.com or www.GoDropless.com .
This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current expectations and are subject to risks and uncertainties which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include risks and uncertainties related to Imprimis' ability to make commercially available its compounded formulations and technologies in a timely manner or at all; its compliance with applicable state and federal pharmacy statutes and regulations; physician interest in prescribing its formulations; risks related to its compounding pharmacy operations; its ability to obtain intellectual property protection for its assets; unexpected new data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. These and additional risks and uncertainties are more fully described in Imprimis' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Such documents may be read free of charge on the SEC's web site at
. Undue reliance should not be placed on forward looking statements, which speak only as of the date they are made. Except as required by law, Imprimis undertakes no obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
Liegner J. Better surgery through chemicals. Presented at the American Society for Cataract and Refractive Surgeons Annual Meeting. April 25-29. Boston, MA.
Galloway MS. Intravitreal placement of antibiotic/steroid as a substitute for post-operative drops following cataract surgery. Presented at the American Society for Cataract and Refractive Surgeons Annual Meeting. April 25-29. Boston, MA.
SOURCE Imprimis Pharmaceuticals, Inc.